Trial · NCT01780935
Adverse events218
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 218
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Choroidal neovascularisation (Fellow untreated eye) | Eye disorders | RBZ 0.5 mg: VA Only (Group I) | 5 | 334 | |
| other | Choroidal neovascularisation (Fellow untreated eye) | Eye disorders | RBZ 0.5 mg: VA and/or OCT (Group II) | 7 | 336 | |
| other | Conjunctival haemorrhage (Study eye) | Eye disorders | RBZ 0.5 mg: VA Only (Group I) | 19 | 334 | |
| other | Conjunctival haemorrhage (Study eye) | Eye disorders | RBZ 0.5 mg: VA and/or OCT (Group II) | 10 | 336 | |
| other | Dry eye (Fellow untreated eye) | Eye disorders | RBZ 0.5 mg: VA Only (Group I) | 7 | 334 | |
| other | Dry eye (Fellow untreated eye) | Eye disorders | RBZ 0.5 mg: VA and/or OCT (Group II) | 4 | 336 | |
| other | Dry eye (Study eye) | Eye disorders | RBZ 0.5 mg: VA Only (Group I) | 10 | 334 | |
| other | Dry eye (Study eye) | Eye disorders | RBZ 0.5 mg: VA and/or OCT (Group II) | 7 | 336 | |
| other | Eye pain (Study eye) | Eye disorders | RBZ 0.5 mg: VA Only (Group I) | 10 | 334 | |
| other | Eye pain (Study eye) | Eye disorders | RBZ 0.5 mg: VA and/or OCT (Group II) | 9 | 336 | |
| other | Neovascular age-related macular degeneration (Fellow untreated eye) | Eye disorders | RBZ 0.5 mg: VA Only (Group I) | 7 | 334 | |
| other | Neovascular age-related macular degeneration (Fellow untreated eye) | Eye disorders | RBZ 0.5 mg: VA and/or OCT (Group II) | 7 | 336 | |
| other | Vitreous floaters (Study eye) | Eye disorders | RBZ 0.5 mg: VA Only (Group I) | 6 | 334 | |
| other | Vitreous floaters (Study eye) | Eye disorders | RBZ 0.5 mg: VA and/or OCT (Group II) | 8 | 336 | |
| other | Bronchitis | Infections and infestations | RBZ 0.5 mg: VA Only (Group I) | 7 | 334 | |
| other | Bronchitis | Infections and infestations | RBZ 0.5 mg: VA and/or OCT (Group II) | 6 | 336 | |
| other | Influenza | Infections and infestations | RBZ 0.5 mg: VA Only (Group I) | 15 | 334 | |
| other | Influenza | Infections and infestations | RBZ 0.5 mg: VA and/or OCT (Group II) | 15 | 336 | |
| other | Nasopharyngitis | Infections and infestations | RBZ 0.5 mg: VA Only (Group I) | 24 | 334 | |
| other | Nasopharyngitis | Infections and infestations | RBZ 0.5 mg: VA and/or OCT (Group II) | 11 | 336 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01780935/events